Our annual survey highlights several academic startups developing immunotherapies as well as ventures focusing on microbiomes, proteostasis, integrin biology, nucleic acid delivery and subcellular imaging. Similarly to recent years, 2016 saw continued enthusiasm for investments in cuttingedge technology and early-stage products. In addition to traditional venture capital firms, corporate venture capital, non-profits and accelerators are now also contributing to seed funding. According to industry newsletter BioCentury, investments in life science companies by corporate venture arms continued to surge, accounting for 30% of startup financing last year.…
Novartis trial validates inflammasome as chronic disease driver
The dramatic finding that an antibody that inhibits interleukin-1b (IL-1b) can reduce the risk of heart attack and stroke is the first clinical evidence that tackling the inflammatory component of cardiovascular disease can benefit patients. Click here to original publication. Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 10 OCTOBER 2017 893…
Speed and oversight: FDA Commissioner Gottlieb acts on pledges
In late August, in a rare tide of bipartisan support, the US Congress passed legislation to reauthorize user fee programs for the next five years… Click here to original publication. Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 10 OCTOBER 2017 …
Epic $12 billion deal and FDA’s approval raise CAR-T to new heights
The strategy of engineering patients’ own T cells for cancer therapy got two major endorsements in late August, one financial and one regulatory… Click here to original publication.…
First metabolic oncology inhibitor gets FDA green light, with record price tag
On August 1, the US Food and Drug Administration (FDA) granted full approval to an isocitrate dehydrogenase 2 (IDH2) enzyme inhibitor to treat relapsed or refractory acute myelogenous leukemia (AML)… Click here to original publication. Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 10 OCTOBER 2017 …
NIH Centers for Accelerated Innovations Program: principles, practices, successes and challenges
There is a chasm in the path from basic biomedical research discoveries to their clinical application owing to inadequate funding for support of proof-of-conceptor validation studies for early-stage development of new technologies… Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 16 | OCTOBER 2017 | 1 Click here to original publication …